Publication details

Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis

Authors	KLUIN-NELEMANS H.C. JAWHAR M. REITER A. VAN ANROOIJ B. GOTLIB J. HARTMANN K. ILLERHAUS A. ELBERINK H.N.G.O. GORSKA A. NIEDOSZYTKO M. LANGE M. SCAFFIDI L. ZANOTTI R. BONADONNA P. PERKINS C. ELENA C. MALCOVATI L. SHOUMARIYEH K. VON BUBNOFF N. MULLER S. TRIGGIANI M. PARENTE R. SCHWAAB J. KUNDI M. FORTINA A.B. CAROPPO F. BROCKOW K. ZINK A. FUCHS D. ANGELOVA-FISCHER I. YAVUZ A,S. DOUBEK Michael MATTSSON M. HAGGLUND H. PANSE J. SIMONOWSKI A. SABATO V. SCHUG T. JENTZSCH M. BREYNAERT C. VARKONYI J. KENNEDY V. HERMINE O. ROSSIGNOL J. AROCK M. VALENT P. SPERR W.R.
Year of publication	2021
Type	Article in Periodical
Magazine / Source	Theranostics
MU Faculty or unit	Central European Institute of Technology
Citation
Web	https://www.thno.org/v11p0292.htm
Doi	http://dx.doi.org/10.7150/thno.51872
Keywords	Mastocytosis; sex difference; cytogenetics; molecular mutations; survival
Description	In systemic mastocytosis (SM), the clinical features and survival vary greatly. Patient-related factors determining the outcome in SM are largely unknown. Methods: We examined the impact of sex on the clinical features, progression-free survival (PFS), and overall survival (OS) in 3403 patients with mastocytosis collected in the registry of the European Competence Network on Mastocytosis (ECNM). The impact of cytogenetic and molecular genetic aberrations on sex differences was analyzed in a subset of patients. Results: Of all patients enrolled, 55.3% were females. However, a male predominance was found in a subset of advanced SM (AdvSM) patients, namely SM with an associated hematologic neoplasm (SM-AHN, 70%; p < 0.001). Correspondingly, organomegaly (male: 23% vs. female: 13%, p = 0.007) was more, whereas skin involvement (male: 71% vs. female: 86%, p = 0.001) was less frequent in males. In all patients together, OS (p < 0.0001) was significantly inferior in males, and also within the WHO sub-categories indolent SM, aggressive SM (ASM) and SM-AHN. PFS was significantly (p = 0.0002) worse in males when all patients were grouped together; due to low numbers of events, this significance persisted only in the subcategory smoldering SM. Finally, prognostically relevant cytogenetic abnormalities (10% vs. 5%, p = 0.006) or molecular aberrations (SRSF2/ASXLI/RUNXI profile; 63% vs. 40%, p = 0.003) were more frequently present in males. Conclusions: Male sex has a major impact on clinical features, disease progression, and survival in mastocytosis. Male patients have an inferior survival, which seems related to the fact that they more frequently develop a multi-mutated AdvSM associated with a high-risk molecular background.